Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Peritonitis | Research article

Low serum parathyroid hormone is a risk factor for peritonitis episodes in incident peritoneal dialysis patients: a retrospective study

Authors: Yuqi Yang, Jingjing Da, Yi Jiang, Jing Yuan, Yan Zha

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Serum parathyroid hormone (PTH) levels have been reported to be associated with infectious mortality in peritoneal dialysis (PD) patients. Peritonitis is the most common and fatal infectious complication, resulting in technique failure, hospital admission and mortality. Whether PTH is associated with peritonitis episodes remains unclear.

Methods

We examined the association of PTH levels and peritonitis incidence in a 7-year cohort of 270 incident PD patients who were maintained on dialysis between January 2012 and December 2018 using Cox proportional hazard regression analyses. Patients were categorized into three groups by serum PTH levels as follows: low-PTH group, PTH < 150 pg/mL; middle-PTH group, PTH 150-300 pg/mL; high-PTH group, PTH > 300 pg/mL.

Results

During a median follow-up of 29.5 (interquartile range 16–49) months, the incidence rate of peritonitis was 0.10 episodes per patient-year. Gram-positive organisms were the most common causative microorganisms (36.2%), and higher percentage of Gram-negative organisms was noted in patients with low PTH levels. Low PTH levels were associated with older age, higher eGFR, higher hemoglobin, calcium levels and lower phosphate, alkaline phosphatase levels. After multivariate adjustment, lower PTH levels were identified as an independent risk factor for peritonitis episodes [hazard ratio 1.643, 95% confidence interval 1.014–2.663, P = 0.044].

Conclusions

Low PTH levels are independently associated with peritonitis in incident PD patients.
Literature
1.
go back to reference Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease-mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. 2017;100:80–6.CrossRef Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease-mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. 2017;100:80–6.CrossRef
2.
go back to reference Bover J, Bailone L, Lopez-Baez V, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30:677–87.CrossRef Bover J, Bailone L, Lopez-Baez V, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30:677–87.CrossRef
3.
go back to reference Torres PAU, Cohen-Solal M. Evaluation of fracture risk in chronic kidney disease. J Nephrol. 2017;30:653–61.CrossRef Torres PAU, Cohen-Solal M. Evaluation of fracture risk in chronic kidney disease. J Nephrol. 2017;30:653–61.CrossRef
4.
go back to reference Kalantar-Zadeh K, Shah A, Duong U, et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;117:S10–21. Kalantar-Zadeh K, Shah A, Duong U, et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;117:S10–21.
5.
go back to reference Toraman A, Aras F, Hekimsoy Z, et al. Is there a relationship between parathyroid hormone and neutrophil lymphocyte ratio or platelet lymphocyte ratio? Acta Endocrinol(Buchar). 2019;5:96–101. Toraman A, Aras F, Hekimsoy Z, et al. Is there a relationship between parathyroid hormone and neutrophil lymphocyte ratio or platelet lymphocyte ratio? Acta Endocrinol(Buchar). 2019;5:96–101.
6.
go back to reference Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens. 2000;9:363–7.CrossRef Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens. 2000;9:363–7.CrossRef
7.
go back to reference Carlstedt E, Ridefelt P, Lind L, et al. Interleukin-6 induced suppression of bovine parathyroid hormone secretion. Biosci Rep. 1999;19:35–42.CrossRef Carlstedt E, Ridefelt P, Lind L, et al. Interleukin-6 induced suppression of bovine parathyroid hormone secretion. Biosci Rep. 1999;19:35–42.CrossRef
8.
go back to reference Dukkipati R, Kovesdy CP, Colman S, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20:243–54.CrossRef Dukkipati R, Kovesdy CP, Colman S, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20:243–54.CrossRef
9.
go back to reference Hong YA, Kim JH, Kim YK, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean J Intern Med. 2020;35:160–70.CrossRef Hong YA, Kim JH, Kim YK, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean J Intern Med. 2020;35:160–70.CrossRef
10.
go back to reference Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64:278–89.CrossRef Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64:278–89.CrossRef
11.
go back to reference Crepaldi C, Possidoni A, Caputo F, et al. Clinical management of patients on peritoneal dialysis in Italy: results from the ATENA study. Clin Kidney J. 2018;11:275–82.CrossRef Crepaldi C, Possidoni A, Caputo F, et al. Clinical management of patients on peritoneal dialysis in Italy: results from the ATENA study. Clin Kidney J. 2018;11:275–82.CrossRef
12.
go back to reference Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.CrossRef Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.CrossRef
13.
go back to reference Johnson DW, Dent H, Hawley CM, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis. 2009;53:290–7.CrossRef Johnson DW, Dent H, Hawley CM, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis. 2009;53:290–7.CrossRef
14.
go back to reference Fan X, Huang R, Wang J, et al. Risk factors for the first episode of peritonitis in southern Chinese continuous ambulatory peritoneal dialysis patients. PLoS One. 2014;9:e107485.CrossRef Fan X, Huang R, Wang J, et al. Risk factors for the first episode of peritonitis in southern Chinese continuous ambulatory peritoneal dialysis patients. PLoS One. 2014;9:e107485.CrossRef
15.
go back to reference Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. Medicine. 2016;95(49):e5569.CrossRef Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. Medicine. 2016;95(49):e5569.CrossRef
16.
go back to reference Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.CrossRef Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.CrossRef
17.
go back to reference Kidney disease: improving global outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2011;7:1–59. Kidney disease: improving global outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2011;7:1–59.
18.
go back to reference Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519–30.CrossRef Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519–30.CrossRef
19.
go back to reference Tangri N, Wagner M, Griffith JL, et al. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom renal registry. Am J Kidney Dis. 2011;57:415–21.CrossRef Tangri N, Wagner M, Griffith JL, et al. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom renal registry. Am J Kidney Dis. 2011;57:415–21.CrossRef
20.
go back to reference Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999;34:1065–74.CrossRef Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999;34:1065–74.CrossRef
21.
go back to reference Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017;18:186.CrossRef Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017;18:186.CrossRef
22.
go back to reference Alemzadeh R, Kichler J. Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. Metab Syndr Relat Disord. 2012;10:422–9.CrossRef Alemzadeh R, Kichler J. Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. Metab Syndr Relat Disord. 2012;10:422–9.CrossRef
23.
go back to reference Lewin E, Ladefoged J, Brandi L, et al. Parathyroid hormone dependent T cell proliferation in uremic rats. Kidney Int. 1993;44:379–84.CrossRef Lewin E, Ladefoged J, Brandi L, et al. Parathyroid hormone dependent T cell proliferation in uremic rats. Kidney Int. 1993;44:379–84.CrossRef
24.
go back to reference Nielsen PK, Rasmussen AK, Butters R, et al. Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun. 1997;238:880–5.CrossRef Nielsen PK, Rasmussen AK, Butters R, et al. Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun. 1997;238:880–5.CrossRef
25.
go back to reference Ozdemir FN, Yakupoglu U, Turan M, et al. Role of parathormone levels on T-cell response in hemodialysis patients. Transplant Proc. 2002;34:2044–5.CrossRef Ozdemir FN, Yakupoglu U, Turan M, et al. Role of parathormone levels on T-cell response in hemodialysis patients. Transplant Proc. 2002;34:2044–5.CrossRef
26.
go back to reference Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39:84–92.CrossRef Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39:84–92.CrossRef
27.
go back to reference Singer RF. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial. 2013;26:40–6.CrossRef Singer RF. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial. 2013;26:40–6.CrossRef
28.
go back to reference Pi HC, Ren YP, Wang Q, et al. Serum 25-hydroxyvitamin D level could predict the risk for peritoneal dialysis-associated peritonitis. Perit Dial Int. 2015;35:729–35.CrossRef Pi HC, Ren YP, Wang Q, et al. Serum 25-hydroxyvitamin D level could predict the risk for peritoneal dialysis-associated peritonitis. Perit Dial Int. 2015;35:729–35.CrossRef
29.
go back to reference Kerschbaum J, Vychytil A, Lhotta K, et al. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One. 2013;8:e67836.CrossRef Kerschbaum J, Vychytil A, Lhotta K, et al. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One. 2013;8:e67836.CrossRef
30.
go back to reference Guhn JY, Chen HC, Chuang HY, et al. Risk factors and risk for mortality of mild hypothyroidism in hemodialysis patients. Am J Kidney Dis. 2002:1245–54. Guhn JY, Chen HC, Chuang HY, et al. Risk factors and risk for mortality of mild hypothyroidism in hemodialysis patients. Am J Kidney Dis. 2002:1245–54.
31.
go back to reference Evenepoel P, Poesen R, Meijers B. The gut–kidney axis. Pediatr Nephrol. 2017;32:2005–14.CrossRef Evenepoel P, Poesen R, Meijers B. The gut–kidney axis. Pediatr Nephrol. 2017;32:2005–14.CrossRef
32.
go back to reference Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol. 2012;77:267–74.CrossRef Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol. 2012;77:267–74.CrossRef
33.
go back to reference Mirzaeian S, Saraf-Bank S, Entezari MH, et al. Effect of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in hemodialysis patients: a double-blind placebo-controlled randomized clinical trial. Nutrition. 2020;73:110713.CrossRef Mirzaeian S, Saraf-Bank S, Entezari MH, et al. Effect of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in hemodialysis patients: a double-blind placebo-controlled randomized clinical trial. Nutrition. 2020;73:110713.CrossRef
34.
go back to reference Kosmadakis G, Albaret J, Corrreia EC, et al. Gastrointestinal disorders in peritoneal Dialysis patients. Am J Nephrol. 2018;48:319–25.CrossRef Kosmadakis G, Albaret J, Corrreia EC, et al. Gastrointestinal disorders in peritoneal Dialysis patients. Am J Nephrol. 2018;48:319–25.CrossRef
Metadata
Title
Low serum parathyroid hormone is a risk factor for peritonitis episodes in incident peritoneal dialysis patients: a retrospective study
Authors
Yuqi Yang
Jingjing Da
Yi Jiang
Jing Yuan
Yan Zha
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02241-0

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.